Keyword Connections

relapsed

Journals

1

1 Leukemia & lymphoma

Research Groups

0

No Research Group Connected

Bibliographies

40

1 Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.

2 Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India

3 Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.

4 Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.

5 The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China.

6 'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

7 Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

8 Comparative study between paired primary and relapsed breast cancer patients based on clinicopathological features and molecular subtypes of breast cancer in Babylon Province

9 Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors.

10 Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

11 Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

12 Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review

13 High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.

14 Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'

15 Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma

16 Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan

17 conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors

18 bendamustine hcl for the treatment of relapsed indolent non-hodgkin&rsquo;s lymphoma

19 dramatic clinical response of relapsed metastatic extramammary paget’s disease to trastuzumab monotherapy

20 the role of allogeneic stem cell transplantation in relapsed/refractory hodgkin's lymphoma patients

21 current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma

22 carfilzomib boosted combination therapy for relapsed multiple myeloma

23 testicular involvement in relapsed hodgkin lymphoma

24 retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

25 tratamento do mieloma múltiplo recidivado relapsed multiple myeloma treatment

26 an intensive approach to treatment for older patients with relapsed isolated npm1 mutated aml

27 gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed t-cell lymphoma

28 inotuzumab ozogamicin: a cd22 mab–drug conjugate for adult relapsed or refractory b-cell precursor acute lymphoblastic leukemia

29 sinonasal lymphoma presenting as a probable sanctuary site for relapsed b acute lymphoblastic leukaemia: a case report and review of the literature

30 a phase ib/ii study of ganetespib with doxorubicin in advanced solid tumors including relapsed-refractory small cell lung cancer

31 autologous bone marrow transplantation in patients relapsed one year after r-chop?

32 Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

33 Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.

34 CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation - Journal of Hematology & Oncology

35 Pentostatin, Cyclophosphamide and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903)

36 Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

37 Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia

38 Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience

39 The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.

40 Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.